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ORIGINAL ARTICLE
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SUMMARY
The impact of hyponatremia on waitlist and post-transplant outcomes following the implementation of MELD-Na-based liver allocation remains
unclear. We investigated waitlist and postliver transplant (LT) outcomes in
patients with hyponatremia before and after implementing MELD-Nabased allocation. Adult patients registered for a primary LT between 2009
and 2021 were identified in the OPTN/UNOS database. Two eras were
defined; pre-MELD-Na and post-MELD-Na. Extreme hyponatremia was
defined as a serum sodium concentration ≤120 mEq/l. Ninety-day waitlist
outcomes and post-LT survival were compared using Fine-Gray proportional hazard and mixed-effects Cox proportional hazard models. A total
of 118 487 patients were eligible (n = 64 940: pre-MELD-Na; n = 53 547:
post-MELD-Na). In the pre-MELD-Na era, extreme hyponatremia at listing was associated with an increased risk of 90-day waitlist mortality ([ref:
135–145] HR: 3.80; 95% CI: 2.97–4.87; P < 0.001) and higher transplant
probability (HR: 1.67; 95% CI: 1.38–2.01; P < 0.001). In the post-MELDNa era, patients with extreme hyponatremia had a proportionally lower
relative risk of waitlist mortality (HR: 2.27; 95% CI 1.60–3.23; P < 0.001)
and proportionally higher transplant probability (HR: 2.12; 95% CI 1.76–
2.55; P < 0.001) as patients with normal serum sodium levels (135–145).
Extreme hyponatremia was associated with a higher risk of 90, 180, and
365-day post-LT survival compared to patients with normal serum sodium
levels. With the introduction of MELD-Na-based allocation, waitlist outcomes have improved in patients with extreme hyponatremia but they
continue to have worse short-term post-LT survival.
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Introduction
In cirrhotic patients, a primary mechanism, contributing
to abnormal sodium homeostasis, is disproportionate
ª 2021 Steunstichting ESOT. Published by John Wiley & Sons Ltd
doi:10.1111/tri.14123

free-water retention resulting from arginine vasopressin
hypersecretion in the setting of circulatory dysfunction
[1]. These changes are typically manifestations of
advanced disease [1] and can be associated with
1
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refractory ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, and death [1,2]. Hyponatremia in cirrhotic patients is relatively common (up to 57% of
inpatients by some reports) and, historically, has been an
independent risk factor for both waitlist dropout and
short-term (90-day) mortality following liver transplantation (LT) [2–5].
In January 2016, the Organ Procurement and Transplantation Network (OPTN)/United Network for Organ
Sharing (UNOS) implemented allocation based on the
Model for End-Stage Liver Disease (MELD)-Na score.
The MELD-Na score is a modification of the original
MELD score that incorporates serum sodium into the
formula [6]. The purpose of this new score in liver graft
allocation was to account for the adverse impact conferred by hyponatremia on waitlist mortality and
improve overall waitlist prognostication [6]. Our group
recently reported that the introduction of MELD-Nabased allocation was associated with improved waitlist
outcomes with lower waitlist mortality and higher transplant rates [7]. The MELD-Na score is calculated and
implemented only if a patient has a MELD of at least
11 using the original MELD equation. In addition, the
MELD-Na equation does not give additional points for
serum sodium levels less than 125 mEq/l, and patients
with severe hyponatremia may not receive higher scores
than patients with more moderate hyponatremia.
Although the incorporation of serum sodium into the
allocation algorithm improves waitlist mortality by
improving access to LT, it is unclear how this impacts
survival benefit and if there is variation in outcomes
based on the degree of hyponatremia. The post-LT
impact of MELD-Na-based allocation on candidates
with extreme hyponatremia remains to be clarified. In
this study, we evaluate post-LT outcomes in patients
with pre-LT hyponatremia and the effect of MELD-Nabased allocation on these outcomes.

Patient and methods

between the implementation of the new policy and the
defined date of the post-MELD-Na era. The same exclusion criteria were applied for the analysis of post-LT outcomes, except patients were excluded if they were
younger than 18 years old at transplant, underwent a living donor liver transplant (LDLT), or had missing
follow-up data. Patients who were listed in the preMELD-Na era and transplanted in the post-MELD-Na
era were excluded from the post-transplant outcome
analysis. A Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) compliant figure of
full patient inclusion and exclusion criteria is shown in
Fig. 1. The study was approved for an institutional review
board (IRB) waiver after IRB review.
Because MELD-Na based allocation was introduced
on January 11, 2016, two time periods were defined
according to the date of LT listing: a pre-MELD-Na era
from January 1, 2009 to January 10, 2016, and a postMELD-Na era from February 11, 2016 to March 5,
2021. As mentioned previously, a one-month washout
period was allowed between the eras. Liver disease etiology was defined by the primary or secondary diagnostic
codes or manual text entries in the dataset and grouped
into alcohol-related liver disease (ALD), hepatitis C
virus-related liver disease (HCV), nonalcoholic steatohepatitis liver disease (NASH), hepatocellular carcinoma
(HCC), malignant and biliary etiologies.
Patients were categorized into six groups according
to the serum sodium level (mEq/l) at listing and at the
time of LT: extreme hyponatremia (Na ≤120), severe
hyponatremia (Na 121–124), moderate hyponatremia
(Na 125–129), mild hyponatremia (Na 130–134), normal sodium (Na 135–145), and hypernatremia (Na
>145). Recipient demographics at LT were collected,
including age, gender, MELD, body mass index (BMI).
Donor characteristics at LT were collected, including
gender, age, BMI, donation after circulatory death
(DCD), hepatitis C virus (HCV) antibody, comorbidities, and cold ischemia time (CIT).

Patient selection

Analysis of waitlist outcomes

This study uses data from the OPTN/UNOS Standard
Transplant and Research file, which contains information
from all patients registered for liver transplantation in the
USA until March 5, 2021. For the analysis of waitlist outcomes, patients with multiorgan transplant listing (except
liver-kidney), re-listing, recipient age <18 at listing, acute
liver failure, status 1A, or who were listed between January 10, 2016 and February 10, 2016 were excluded. The
latter was regarded as a one-month washout period

Ninety-day waitlist outcomes were analyzed using a competing risk analysis with outcomes, including improvement on the waitlist (removal code 12), transplantation
(removal codes 2–4, 14, 18, 19, 21, and 22), or death,
including removal for being too sick (removal codes 5, 8,
and 13). Data was censored if none of the abovementioned events had occurred before the end of the set
period. Patients who received LDLT were censored at the
time of LDLT receipt. Because differences in follow-up
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Figure 1 STROBE diagram of cohorts included and excluded.

time can result in withdrawal bias, patients registered in
each era were censored on the last day of that era (January 11, 2016, and March 5, 2021, respectively).

Analysis of post-LT outcomes and comparison of the
hazard of mortality
Short-term post-LT outcomes were evaluated and compared between eras, including 90-day and 1-year patient
Transplant International 2021;
ª 2021 Steunstichting ESOT. Published by John Wiley & Sons Ltd

survival. Both unadjusted and adjusted survival analyses
were performed. Risk factors for post-LT mortality were
evaluated adjusting for the following variables present at
the time of LT: recipient age, encephalopathy, ascites,
recipient life support, MELD exception, disease etiology,
hyponatremia levels, recipient diabetes, recipient BMI,
International normalized ratio (INR), Creatinine, Bilirubin, liver-kidney listing, dialysis requirement during the
week before LT, CIT, Karnofsky score, waitlist time,
3
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donor age, donor BMI, and DCD donor. In the preMELD-Na era, the MELD score is the MELD score,
whereas, in the post-MELD-Na era, the MELD represents the MELD-Na. To overcome this differential calculation in the MELD score, adjustments were made for
the individual MELD score components (bilirubin, INR,
and creatinine). A mixed-effects cox regression model
was constructed where the transplant center was treated
as a random effect. The interaction between the sodium
categories and the MELD-Na era were evaluated in the
adjusted multivariable models. The primary cause of
death was captured by the variable name COD and up
to two contributory causes of death were captured by
the COD2 and COD3 variables, respectively.

Statistical analysis
Descriptive data for continuous variables were expressed
as means with standard deviation if the distribution was
normal and medians with interquartile range (IQR) if
the distribution was non-normal. These were compared
using the Student t-test and Mann-Whitney U test,
respectively. Categorical variables were expressed as
numbers and percentages and were compared using chisquare and Fischer exact test. Patients were analyzed
from the time of LT using Kaplan-Meier analysis with
log-rank tests. Multiple pairwise comparisons between
groups with corrections for multiple testing were performed using the Benjamini-Hochberg method. Cox
proportional hazard regression models were constructed
to evaluate the association of extreme hyponatremia on
post-LT patient survival. For the waitlist analysis,
instead of a Kaplan-Meier approach, which censors for
competing events, a cumulative incidence approach was
used to account for the presence of competing risks of
transplant and waitlist dropout due to mortality [8].
The cumulative incidence was calculated using subdistribution estimates for each cause. A Gray’s modified
log-rank test was used to compare sub-distribution estimates for each cause (unadjusted incidence estimated)
of waitlist event. Multiple pairwise comparisons between
groups with corrections for multiple testing were performed using the Bonferroni method. For assessing the
relative change in the hazard of waitlist dropout due to
mortality, a Fine-Gray proportional sub-distribution
hazard model was used to account for transplant as a
competing event [9]. Flexible hazard ratio curves were
constructed using “smoothing splines” to allow for the
nonlinear aspect of serum sodium as a continuous predictor of survival. A P-value <0.05 was considered statistically significant for all analyses. All statistical
4

analyses were performed using R (R version 4.0.3
[2020-10-10], R foundation for Statistical Computing,
Vienna, Austria URL http://www.R-project.org/). Competing risk analysis was performed using the package
‘cmprsk’. Mixed-effects cox regression was performed
using the package ‘survival’ and ‘coxme’.

Results
Waitlist outcome analysis
A total of 118 487 patients were identified for the analysis
of waitlist outcomes (N = 64 940 Pre-MELD-Na and
N = 53 547 Post-MELD-Na). Waitlist characteristics are
compared between eras in Table 1. The majority of
patients had a normal serum sodium concentration at
listing in both the pre- and post-MELD-Na era (135–145,
68.1% vs. 67.3%; P < 0.001). Patients with a serum
sodium concentration of ≤ 120 at listing comprised 0.5%
of patients in the pre-MELD-Na era and 0.6% in the
post-MELD-Na era (P < 0.001). Of the extreme hyponatremic cohort at listing (n = 295 and n = 207 in the preand post-MELD-Na era, respectively), 3 (1.0%) required
dialysis in the week prior to listing in the pre-MELD era
and 6 (2.9%) in the post-MELD era (Table S1). Patients
with extreme hyponatremia had a higher 90-day cumulative incidence of waitlist dropout due to death compared
to patients with higher (135–145, 130–134, 125–129, and
121–124) sodium levels in the pre-MELD-Na era
(P < 0.001) but similar rates compared to patients with
the highest serum sodium concentrations (>145; Fig. 2a).
Similarly, patients with extreme hyponatremia had a
higher transplant probability compared with patients
with higher sodium levels (135–145, 130–134) in the preMELD-Na era (P < 0.001; Fig. 2b). Significant differences were also observed in the post-MELD-Na era,
where patients with extreme hyponatremia had similar
90-day waitlist mortality as patients with higher serum
sodium concentration (121–124, 125–129, >145) but
higher waitlist mortality than patients with a serum
sodium concentration of 130–134 and 135–145 (Fig. 3a).
The cumulative 90-day transplant probability was highest
in patients with extreme hyponatremia than all other
serum sodium concentrations except for patients with a
serum sodium concentration between 121 and 124 mEq/l
(Fig. 3b).
In patients with extreme hyponatremia, the cumulative
incidence of 90-day waitlist dropout due to death was
lower post-MELD-Na (P < 0.001; Fig. S1a), and the
cumulative incidence of 90-day transplant probability was
higher post-MELD-Na (P < 0.001; Fig. S1b) compared to
Transplant International 2021;
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Table 1. Patient characteristics (waitlist).
Pre-MELD-Na (N = 64 940)
Serum sodium concentration at listing, mEq/l, n (%)
N-missing
40
135–145
44 194 (68.1%)
130–134
14 270 (22.0%)
125–129
4347 (6.7%)
120–124
1118 (1.7%)
≤120
330 (0.5%)
>145
641 (1.0%)
Recipient sex, n (%)
Female
22 335 (34.4%)
Male
42 605 (65.6%)
Recipient age (years), median (Q1, Q3)
58 (52, 63)
MELD score at listing, median (Q1, Q3)
15 (11, 21)
Days on waitlist, median (Q1, Q3)
204 (50, 572)
Hepatocellular carcinoma, n (%)
14 964 (23.0%)
Malignant indication, n (%)
15 289 (23.5%)
Alcohol-related liver disease, n (%)
18 358 (28.3%)
Hepatitis C virus-related liver disease, n (%)
26 033 (40.1%)
Non-alcoholic steatohepatitis, n (%)
8804 (13.6%)
Biliary etiology of liver disease, n (%)
4889 (7.5%)
Recipient diabetes, n (%)
18 148 (28.1%)
(Missing)
332
Functional status, n (%)
10–30%
7906 (12.5%)
40–100%
55 464 (87.5%)
(Missing)
1570
Dialysis week prior to listing, n (%)
4216 (6.5%)
(Missing)
15
Exception points, n (%)
15 467 (23.8%)
Life support at listing, n (%)
1353 (2.1%)
Missing
3

Post-MELD-Na (N = 53 547)

P value

28
36 041 (67.3%)
11 737 (21.9%)
3950 (7.4%)
1009 (1.9%)
307 (0.6%)
475 (0.9%)

<0.001*

19 623 (36.6%)
33 924 (63.4%)
58 (50, 64)
18 (11, 26)
140 (25, 348)
11 476 (21.4%)
11 994 (22.4%)
20 654 (38.6%)
10 339 (19.3%)
12 682 (23.7%)
4068 (7.6%)
16 215 (30.6%)
581

<0.001*

8336 (16.0%)
43 855 (84.0%)
1356
4694 (8.8%)
24
8317 (15.5%)
1519 (2.9%)
498

<0.001†
<0.001†
<0.001†
<0.001*
0.047*
<0.001*
<0.001*
<0.001*
0.657*
<0.001*
<0.001*
<0.001*
<0.001*
<0.001*

*Pearson’s Chi-squared test.
†

Kruskal-Wallis rank sum test.

pre-MELD-Na. Similar findings were observed for patients
without extreme hyponatremia (Fig. S2a,b).
In extreme hyponatremic patients, using Fine-Gray
proportional hazard models, the post-MELD-Na era
was protective for 90-day waitlist survival [subdistribution HR (sHR) 0.44, 95% CI 0.28–0.68;
P < 0.001] and was associated with an increased chance
for receiving a transplant within 90 days (HR 1.89, 95%
CI 1.48–2.41; P < 0.001; Fig. S2). In the pre-MELD era,
extreme hyponatremia at listing was associated with an
increased risk of 90-day waitlist mortality (ref: 135–145,
sHR 3.80, 95% CI 2.97–4.87; P < 0.001) and a higher
likelihood of transplant within 90-days (ref: 135–145,
sHR 1.67, 95% CI 1.38–2.01; P < 0.001; Fig. S3a,b). In
the post-MELD-Na era, extreme hyponatremia had a
proportionally lower risk (although statistically significantly higher) of 90-day waitlist mortality (ref: 135–145,
Transplant International 2021;
ª 2021 Steunstichting ESOT. Published by John Wiley & Sons Ltd

sHR 2.27, 95% CI 1.60–3.23; P < 0.001) and a proportionally higher chance of transplant (ref: 135–145, sHR
2.12, 95% CI 1.76–2.55; P < 0.001) as patients with
normal serum sodium levels at listing (Fig. S2a,b).

Analysis of patients who underwent LT
A total of 58 841 patients were analyzed, including
30 912 in the Pre-MELD-Na era and 27 929 in the
Post-MELD-Na Era (Fig. 1). There was a small (0.5%)
and a similar proportion of patients with serum sodium
≤120 pre- and post-MELD-Na. MELD scores were
higher in the post-MELD-Na era [median (IQR) 21
(13–31) vs. 24 (16–32) P < 0.001], and the median
overall time on the waitlist was shorter post-MELD-Na
[days (IQR) 91 (20–256) vs. 61 (11–226); P < 0.001]. A
higher proportion of DCD LTs was performed in the
5
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Figure 2 (a) Pre-MELD-Na era 90-day waitlist dropout for death or too sick by serum sodium concentration. (b) Pre-MELD-Na era 90-day transplant probability by serum sodium concentration. (c) Post-MELD-Na era 90-day waitlist dropout for death or too sick by serum sodium concentration. (d) Post-MELD-Na era 90-day transplant probability by serum sodium concentration.

Figure 3 (a) Post-MELD-Na era 90-day waitlist dropout for death or too sick by serum sodium concentration. (b) Post-MELD-Na era 90-day
transplant probability by serum sodium concentration.

post-MELD-Na era (5.7% vs. 8.7%; P < 0.001; Table 2).
Patient characteristics stratified by serum sodium concentration at LT for the pre-MELD-Na and postMELD-Na eras can be seen in Tables S2 and S3. For
extreme hyponatremic patients who underwent transplant (154 and 143 in the pre- and post-MELD-Na era,
respectively) 7 (4.5%) required dialysis in the week
6

prior to LT in the pre-MELD era and 4 (2.8%) in the
post-MELD era (Table S1).

Unadjusted post-LT survival analysis
The 30, 90, 180-, and 365-day post-LT survival in
patients with extreme hyponatremia in the pre-MELDTransplant International 2021;
ª 2021 Steunstichting ESOT. Published by John Wiley & Sons Ltd
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Table 2. Patient characteristics (LT).
Pre-MELD-Na (N = 30 912)
Serum sodium concentration at liver transplant, mEq/l, n (%)
135–145
19 729 (63.8%)
130–134
7292 (23.6%)
125–129
2540 (8.2%)
121–124
566 (1.8%)
≤120
154 (0.5%)
>145
629 (2.0%)
(Missing)
2
Recipient sex, n (%)
Female
9724 (31.5%)
Male
21 188 (68.5%)
Recipient age (years), Median (Q1, Q3)
57 (51, 62)
In intensive care unit at liver transplant, n (%)
3662 (11.8)
MELD at liver transplant, median (Q1, Q3)
21 (13, 31)
Days on the waitlist, median (Q1, Q3)
91 (20, 256)
Recipient diabetes, n (%)
8533 (27.8%)
N-missing
164
Functional status, n (%)
N-missing
266
40–100%
22 033 (71.9%)
10–30%
8613 (28.1%)
Dialysis in the week prior to liver transplant, n (%)
4516 (14.6%)
(Missing)
0
Hepatocellular carcinoma, n (%)
8764 (28.4%)
Malignant indication, n (%)
8861 (28.7%)
Alcohol-related liver disease, n (%)
8250 (26.7%)
Hepatitis C virus-related liver disease, n (%)
12 858 (41.6%)
Non-alcoholic steatohepatitis, n (%)
4063 (13.1%)
Biliary etiology of liver disease, n (%)
2217 (7.2%)
Follow-up time, days, Median (Q1, Q3)
2165 (1427, 2905)
Length of stay, Median (Q1, Q3)
10 (7, 16)
Recipient BMI, Median (Q1, Q3)
28.0 (24.5, 32.3)
Donor sex, n (%)
Female
12 452 (40.3%)
Male
18 460 (59.7%)
Donor BMI, Median (Q1, Q3)
26.69 (23.37, 30.99)
Donation after circulatory death, n (%)
1767 (5.7%)
Exception points, n (%)
11 633 (44.8%)
N-missing
4920
Life support at liver transplant, n (%)
2180 (7.1%)
N-missing
0

Post-MELD-Na (N = 27 929)

P value

16 715 (59.9%)
7031 (25.2%)
2915 (10.4%)
719 (2.6%)
143 (0.5%)
402 (1.4%)
4

<0.001*

9638 (34.5%)
18 291 (65.5%)
58 (50, 64)
3816 (13.7)
24 (16, 32)
61 (11, 226)
8378 (30.0%)
37

<0.001*

333
19 394 (70.3%)
8202 (29.7%)
4903 (17.6%)
143
5856 (21.0%)
6090 (21.8%)
11 260 (40.3%)
5379 (19.3%)
6691 (24.0%)
1973 (7.1%)
384 (184, 863)
10 (7, 16)
28.4 (24.7, 32.8)

<0.001*

10 941 (39.2%)
16 988 (60.8%)
27.25 (23.67, 31.76)
2423 (8.7%)
6430 (25.2%)
2427
2303 (8.2%)
12

<0.001†
<0.001*
<0.001†
<0.001†
<0.001*

<0.001*
<0.001*
<0.001*
<0.001†
<0.001†
<0.001†
0.612†
<0.001†
<0.001†
<0.001†
0.044*
<0.001†
<0.001*
0.172†
<0.001*

BMI, body mass index; MELD, model for end-stage liver disease; Q1, Q3, interquartile range.
*Pearson’s Chi-squared test.
†

Kruskal-Wallis rank sum test.

Na era were 95.5% (95% CI 92.2–98.8), 93.5% (95% CI
89.7–97.5), 89.6% (95% CI 84.9–94.5), and 85.6% (95%
CI 80.3–91.4), respectively, compared to 97.6% (95% CI
97.3–97.8), 95.8% (95% CI 95.5–96.1), 94.0% (95% CI
93.7–94.3), and 91.3% (95% CI 90.9–91.7), respectively,
in patients with normal serum sodium levels (30-day
P = 0.17, 90-day P = 0.32, 180-day P = 0.06, and 365Transplant International 2021;
ª 2021 Steunstichting ESOT. Published by John Wiley & Sons Ltd

day P = 0.03). The 30, 90, 180, and 365-day post-LT
survival in patients with extreme hyponatremia in the
post-MELD-Na era were 95.6% (95% CI 92.3–99.1),
93.3% (95% CI 89.2–97.6), 91.0% (95% CI 86.2–96.0),
and 89.3% (95% CI 84.1–94.8), respectively, compared
to 97.7% (95% CI 97.5–98.0), 96.3% (95% CI 96.0–
96.6), 95.1% (95% CI 94.7–95.4), and 92.7% (95% CI
7
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92.3–93.2) in patients with normal serum sodium levels
(30-day P = 0.18, 90-day P = 0.14, 180-day P = 0.06,
365-day P = 0.17; Figs 4 and S4).
In the pre-MELD-Na era, patients with hypernatremia (Na >145) had the worst 90-day post-LT survival
compared to all sodium levels except compared to
patients with extreme hyponatremia where the unadjusted survival was equivalent (P = 0.43; Fig. 4a). In the
post-MELD-Na era, patients with extreme hyponatremia
had a statistically significantly worse 90- and 365-day
post-LT survival compared to a serum sodium concentration of 121–124, and a nonstatistically significant different unadjusted survival from a serum sodium
concentration of 125–129, 130–134, 135–145, and over
145 (Fig. 4b).
Patients with extreme hyponatremia had a similar 90day and 365-day post-LT survival in both the preMELD-Na and post-MELD-Na eras (Fig. S5).

Cox proportional hazard analysis
On the mixed-effects multivariable Cox proportional
hazard analysis for 90-day post-LT survival where transplant center was treated as a random effect, adjusting
for bilirubin at LT, creatinine at LT, INR at LT, DCD,
recipient age, encephalopathy, ascites, etiology of liver
disease, recipient diabetes, recipient BMI, functional status, recipient life support at LT, exception points, donor
age, donor BMI, simultaneous liver-kidney transplant

listing, dialysis status pre-LT, and Era (pre-MELD-Na
reference), both extreme hyponatremia and hypernatremia were associated with patient death (HR 2.28,
95% CI 1.43–3.64; P = 0.03 and HR 2.05, 95% 1.59–
2.64; P < 0.001). These findings persisted up to 180days (extreme hyponatremia (ref: 135–145) HR 2.45,
95% CI 1.67–3.61; P < 0.001) and up to 365-days postLT (extreme hyponatremia (ref: 135–145) HR 2.16, 95%
CI 1.53–3.04; P < 0.001). In none of the models did the
association of extreme hyponatremia with death vary
depending on the era [serum sodium concentration *
MELD-era (interaction)].
In the pre-MELD-Na era, extreme hyponatremia had
a higher risk for post-LT 90-day mortality as a normal
serum sodium level (HR 2.13, 95% CI 1.08–4.18;
P = 0.03; Fig. 5a) The risk remained higher up to 180days post-LT (ref: 135–145, HR 2.42, 95% CI 1.43–4.09;
P < 0.001) and up to 365-days post-LT (ref: 135–145,
HR 2.10, 95% CI 1.32–3.35; P = 0.001; Fig. S6a). In the
post-MELD-Na era, extreme hyponatremia had a higher
hazard for post-LT 90-day mortality relative to a normal serum sodium concentration (HR 2.40, 95% CI
1.21–4.75; P = 0.01; Fig. 5b). This effect persisted up to
180-days post-LT (ref: 135–145, HR 2.51, 1.39–4.53;
P = 0.002) and up to 365-days post-LT (ref: 135–145,
HR 2.16, 95% CI 1.25–3.73; P = 0.005; Fig. S6b). A
steeper increase in hazard below a serum sodium concentration of 120 was observed in the post-MELD-Na
era compared to the pre-MELD-Na era when serum

Figure 4 (a) 90-day post-LT survival stratified by serum sodium at LT (pre-MELD-Na era). (b) 90-day post-LT survival stratified by serum sodium
at LT (post-MELD-Na era).
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Figure 5 (a) Mixed effects Cox proportional hazard model forest plot for post-LT 90-day mortality in pre-MELD-Na era by serum sodium concentration (ref: serum sodium concentration 135–145 mEq/l). Adjusted for recipient factors (sodium level at LT, age, encephalopathy, ascites,
liver disease etiology [ALD, HCV, NASH, HCC], life support, diabetes, bilirubin, INR, creatinine, dialysis requirement, BMI, functional status,
exception points, liver kidney listing), and donor factors (DCD, CIT, age, BMI), and era. (b) Cox proportional hazard model forest plot for postLT 90-day mortality in post-MELD-Na era by serum sodium concentration (ref: serum sodium concentration 135–145 mEq/l. Adjusted for recipient factors (sodium level at LT, age, encephalopathy, ascites, liver disease etiology [ALD, HCV, NASH, HCC], life support, diabetes, bilirubin,
INR, creatinine, dialysis requirement, BMI, functional status, exception points, liver kidney listing), and donor factors (DCD, CIT, age, BMI), and
era.

sodium concentration was modeled using penalized
smoothing spline on adjusted analysis (Fig. S7).

Discussion
This study demonstrates that while waitlist outcomes
for extremely hyponatremic patients have improved
through lower waitlist mortality rates (ref: normal
serum sodium, risk-adjusted sHR 2.27, 95% CI 1.60–
3.23; P < 0.001) and higher transplantation rates (ref:
normal serum sodium, risk-adjusted sHR 2.12, 95% CI
1.76–2.55; P < 0.001), the same patients continue to
have worse short-term post-LT outcomes (ref: normal
serum sodium, risk-adjusted mortality HR 2.40, 95% CI
1.21–4.75; P = 0.01) relative to other serum sodium
concentrations in the post-MELD-Na era. Our group
recently reported the effects of the MELD-Na-based
allocation on waitlist and post-LT outcomes and
demonstrated that the new allocation score was associated with improved waitlist outcomes in patients with
hyponatremia [7]. This present study further investigated the impact of the policy change, concentrating on
patients with extreme hyponatremia. An evaluation
specifically focused on patients with extreme hyponatremia has not been performed, and they are often
Transplant International 2021;
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grouped with abnormal yet higher serum sodium concentrations (e.g., <125 mEq/l). Consequently, the better
outcomes of patients with higher sodium levels (i.e.,
>120 but <125) may mask the specific outcomes in the
extremely hyponatremic group. This study’s findings
highlight that caution should be exercised in proceeding
with LT in these patients, and efforts should be made to
optimize patients for LT to mitigate adverse short-term
post-LT outcomes.
The MELD-Na score was developed over several renditions [3,5]. Biggins et al. [3] incorporated Na into the
MELD score using a prospective multicenter database of
753 patients. In this model, the lower and upper limits
of serum sodium were established at 120 and 135,
assuming a linear relationship between those limits and
waitlist mortality. The lower limit was selected because
a linear relationship for worse outcomes did not extend
past this cutoff, there were few patients below this point
and the perceived need for a “cap” similar to creatinine
in the original MELD formula [3]. The authors highlighted that incorporating of sodium into the allocation
system might favor severely hyponatremic patients at
risk of neurologic problems following transplantation
and that it was the transplant center’s responsibility to
identify patients who were too high risk to undergo
9

Ivanics et al.

transplantation [3,5]. The present MELD-Na score limits sodium in the range of 125–140 mEq/l, and concentrations beyond these cutoffs do not result in higher
scores. Concerns have been raised that the prioritization
of hyponatremic patients by the present MELD-Na system might adversely affect post-LT outcomes [10]. Our
study demonstrates this is predominantly limited to
patients with extreme hyponatremia.
Several studies have demonstrated an independent
association between hyponatremia and worse waitlist
and short-term transplant outcomes, primarily due to
neurological disorders, renal failure, and infection [11–
13]. Hyponatremia is considered a marker of advanced
cirrhosis and results, in part, from significant hemodynamic abnormalities that lead to impairment in body
water homeostasis [1,14]. The LT allocation policy in
the USA is based on allocating grafts according to the
“sickest first” to rescue patients from likely death. Allocation is not based on transplant survival, which is left
to individual centers to risk assess guided, in part, by
regulatory guardrails. Because the MELD score’s ability
to predict mortality was suboptimal in hyponatremic
patients, the MELD-Na score was developed to improve
accuracy. While this has resulted in overall favorable
outcomes for hyponatremia patients, patients with
extreme hyponatremia appear to have worse short-term
post-LT outcomes than other degrees of hyponatremia.
Apart from the aforementioned pathophysiologic reasons, extremely hyponatremic patients have overall
higher MELD scores, shorter waitlist times, and worse
functional status than patients without extreme hyponatremia. The exact reason why the difference in transplant survival is more pronounced in the post-MELDNa era is not entirely clear. One explanation may be
that the accelerated waitlist process, supported by a
shorter waitlist time in extreme hyponatremic patients
in the post-MELD-Na era, while increasing the chance
of LT, may result in less opportunity for preoperative
optimization decrease the likelihood of poorer candidates dropping off the waitlist and instead of proceeding to LT. While risk factors could not be determined
within the extremely hyponatremic group, given the
small number of events, potentially modifiable donor
factors associated with decreased 90-day post-LT survival were the use of DCD grafts and longer CIT. Recipient selection could reflect the increased early mortality
risk seen with older recipient age, higher recipient BMI,
worse functional status, and need for life support. Thus,
these should be considered when mitigating the risk of
early mortality post-LT by avoiding compounding factors. For instance, patients with extreme hyponatremia
10

might potentially benefit from additional medical optimization rather than proceeding more rapidly to LT
with a marginal graft such as a DCD liver.
Data on the management of patients with severe
hyponatremia entering into LT are limited and there are
no succinct society or working group guidelines in this
specific setting. An absolute sodium level cutoff below
which proceeding with LT is contraindicated has not
been established due to the complex physiology it represents. The sodium level is a dynamic variable that can be
acutely or chronically altered, especially with diuretic
therapy, medical intervention, and dialysis. The latter was
adjusted for in our multivariable analysis. Consequently,
serum sodium levels should be taken in the context of the
entire clinical picture of any transplant candidate. Leise
et al. [15] described results of a survey administered to
20 moderate to large-sized LT programs in the USA,
which highlighted that only 45% (9 out of 20) had an
absolute threshold of serum sodium for not proceeding
with transplantation. This threshold ranged between
≤125 and ≤120 mEq/l. Moreover, an even smaller minority (30%) of programs had standard protocols for
managing hyponatremia [15]. It should be recognized
that preoperative optimization may not be feasible in all
hyponatremic patients, given the urgent need for LT.
Consequently, if the emphasis is placed on preoperative
sodium correction, there is a risk that a patient may deteriorate and lose their opportunity for transplantation.
Several critical observations might help guide therapy
of hyponatremia in patients undergoing imminent transplant. In the general patient population, the risk of osmotic demyelination syndrome (ODS) is greatest when
serum sodium is corrected more than 12 mEq/l within
24 h [16]. For patients in general, a European expert
group recommends that serum sodium correction not
exceed 10 mEq/l in the first 24 h [17] and a US expert
group limits the correction to 8 mEq/l per day [18]. In
addition, Yun et al. [10] using a multicenter US database
demonstrate a pretransplant sodium of <125 mEq/l is
significantly associated with post-transplant CPM at an
incidence of 4.6%. At our center, we build on these
observations to inform our approach to pretransplant
hyponatremia. At the time of donor offer, we use conventional measures, including the use of saline or hypertonic
saline, to increase serum sodium to at least 120 mEq/l. In
patients with a sodium between 120 and 125 mEq/l
entering into surgery, we use an intraoperative continuous veno-venous hemofiltration (CVVH) protocol to
facilitate a controlled and gradual increase in the serum
concentration [16] and have not seen ODS or other
adverse outcomes. In the unusual case that the sodium
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cannot be increased to 120 mEq/prior to surgery, the
transplant is typically cancelled.
The use of intra-operative CVVH protocols [19] to
control sodium stabilization is particularly useful in LT,
where potential requirements for intraoperative fluid
and blood product administration can lead to rapid
sodium fluctuations with the potential for (ODS)
[10,20]. Gradual sodium correction can be achieved
using hypotonic replacement fluid composed of successively higher sodium concentrations [21]. The trend in
serum sodium correction is measured with frequent
measurements (0, 1, and every 2 h) [19]. The slow and
continuous sodium correction that CVVH can achieve
has been demonstrated to be safe and feasible in
patients with severe hyponatremia with and without
underlying liver dysfunction [21,22]. Moreover, one
small study demonstrated the use of CVVH to be associated with a nonstatistically improved post-LT survival
in high MELD-score patients with acute kidney injury
(1-year survival 86% with CVVH vs. 71% without
CVVH), a scenario that has become increasingly common in the Share 35 era [23,24]. Additionally, the intraoperative use of CVVH has not been found to be
associated with an increased operative time or blood
product requirement [23].
This study is limited by its retrospective nature, with
the potential for misclassification and selection bias.
Although covariate adjustments were made for group
comparisons, there is always a potential for residual and
unmeasured confounding. The sodium levels were analyzed at only two time points, listing, and LT. Information on diuretic use and volume status is not captured
in the dataset. However, within this context, it should
be noted that chronic hyponatremia in cirrhotic patients
is difficult to alter [25]. One of the potential risks of LT
in patients with extreme hyponatremia are neurological
complications, including ODS. We attempted to determine a possible association, but the mortality numbers
available for patients with extreme hyponatremia are
too limited. Moreover, intra-operative CVVH use is not
captured in the database, and it thus remains unclear
whether the use of such strategies may lead to improved
outcomes. The OPTN/UNOS registry lacks other
detailed clinical information. Lastly, operative variables,
including treatment administered to correct serum
sodium abnormalities and the degree to which sodium
was adjusted, are unavailable in the database and may
have impacted short-term post-LT outcomes.
This study demonstrates that waitlist outcomes have
improved for patients with extreme hyponatremic in the
post-MELD era. In contrast, these patients continue to
Transplant International 2021;
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have worse short-term post-LT survival in the postMELD-Na era relative to higher serum sodium concentrations. This highlights the need to optimize patients in the
perioperative period and the need to define algorithms to
identify serum sodium levels beyond which proceeding
with LT exceeds the risk of remaining on the waitlist.
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Figure S1. (a) Extreme hyponatremia 90-day waitlist
dropout due to death or too sick. (b) Extreme hyponatremia 90-day waitlist probability of transplantation.
Figure S2. (a) Patients without extreme hyponatremia
90-day waitlist dropout due to death or too sick. (b)
Patients without extreme hyponatremia 90-day waitlist
probability of transplantation.
Figure S3. Effect on post-MELD-Na era on waitlist mortality and transplant probability (ref: pre-MELD-Na).
Adjusted for age at listing, INR at listing, bilirubin at listing,
creatinine at listing, BMI at registration, sex, diabetes, functional status, sodium concentration at listing, life support
at listing, liverkidney listing, dialysis at registration, ascites
at listing, encephalopathy at listing, diagnosis of HCC, diagnosis of ALD, diagnosis of NASH, and a diagnosis of HCV.
Figure S4. (a) Fine-Gray multivariable model for 90day waitlist mortality (subdistribution Hazard ratio for 90day waitlist mortality for extreme hyponatremic patients
(ref: 135–145). Adjusted for age at listing, INR at listing,
bilirubin at listing, creatinine at listing, BMI at registration,
sex, diabetes, functional status, sodium concentration at
listing, life support at listing, liver-kidney listing, dialysis at
registration, ascites at listing, encephalopathy at listing,
diagnosis of HCC, diagnosis of ALD, diagnosis of NASH,
and a diagnosis of HCV. (b) Fine-Gray multivariable
model for 90-day likelihood of transplant (subdistribution
Hazard ratio for 90-day waitlist mortality for extreme
hyponatremic patients (ref: 135–145) Adjusted for age at
listing, INR at listing, bilirubin at listing, creatinine at listing, BMI at registration, sex, diabetes, functional status,
sodium concentration at listing, life support at listing,
liver-kidney listing, dialysis at registration, ascites at listing,
encephalopathy at listing, diagnosis of HCC, diagnosis of
ALD, diagnosis of NASH, and a diagnosis of HCV.
Figure S5. (a) 365-day post-LT survival stratified by
serum sodium at LT (pre-MELD-Na era). (b) 365-day
post-LT survival stratified by serum sodium at LT
(post-MELD-Na era).
Figure S6. (a) 90-day post-LT survival in patients
with extreme hyponatremia stratified by era. (b) 365-

day post-LT survival in patients with extreme hyponatremia stratified by era.
Figure S7. (a) Mixed effects Cox proportional hazard
model forest plot for post-LT 365-day mortality in preMELD-Na era by serum sodium concentration (ref:
serum sodium concentration 135–145 mEq/l). Adjusted
for recipient factors (sodium level at LT, age,
encephalopathy, ascites, liver disease etiology [ALD,
HCV, NASH, HCC], life support, diabetes, bilirubin,
INR, creatinine, dialysis requirement, BMI, functional
status, exception points, liver kidney listing), and donor
factors (DCD, CIT, age, BMI), and era. (b) Cox proportional hazard model forest plot for post-LT 365-day
mortality in post-MELD-Na era by serum sodium concentration (ref: serum sodium concentration 135–
145 mEq/l). Adjusted for recipient factors (sodium level
at LT, age, encephalopathy, ascites, liver disease etiology
[ALD, HCV, NASH, HCC], life support, diabetes,
bilirubin, INR, creatinine, dialysis requirement, BMI,
functional status, exception points, liver kidney listing),
and donor factors (DCD, CIT, age, BMI), and era.
Figure S8. (a) Mixed effects Cox proportional hazard
model with a penalized spline fit of sodium concentration
for post-LT 90-day survival in the pre-MELD-Na era (adjusted for bilirubin at transplant, INR at transplant, creatinine at transplant, recipient age, encephalopathy,
ascites, recipient diabetes, dialysis before LT, etiology of
liver disease, recipient BMI, functional status, life support, exception points, liver-kidney listing, DCD, CIT,
donor age, and donor BMI). (b) Mixed effects Cox proportional hazard model with a penalized spline fit of
sodium concentration for post-LT 90-day survival in the
post-MELD-Na era (adjusted for bilirubin at transplant,
INR at transplant, creatinine at transplant, recipient age,
encephalopathy, ascites, recipient diabetes, dialysis before
LT, etiology of liver disease, recipient BMI, functional
status, life support, exception points, liver-kidney listing,
DCD, CIT, donor age, and donor BMI).
Table S1. Dialysis status by sodium group (preMELD-Na and post-MELD-Na).
Table S2. Patient characteristics by sodium group
(pre-MELD-Na).
Table S3. Patient characteristics by sodium group
(post-MELD-Na).
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